IntrepidX hires Hatch-Waxman eDiscovery veteran Taylor Judd

IntrepidX said July 23 it hired Taylor Judd as director of business development to help expand its pharmaceutical litigation and corporate legal work. The move deepens the company’s push into complex eDiscovery matters across regulated industries, including banking, finance and e-commerce.

Why it matters: - IntrepidX is trying to grow in high-stakes legal work where speed, defensibility and confidentiality can shape case outcomes. - The hire adds a business development lead with direct experience in Hatch-Waxman, pharmaceutical IP disputes and corporate legal workflows. - The company is also positioning its technology stack, including XSuite, as a differentiator in crowded eDiscovery markets.

What happened: - IntrepidX announced that Taylor Judd joined the company as director of business development. - Judd will support strategic growth across pharmaceutical litigation, corporate legal and other complex eDiscovery matters. - The company said the expansion also targets banking and finance and e-commerce work. - The announcement was made July 23, 2026, from San Diego.

The details: - Judd has more than 15 years of experience helping law firms and corporate legal teams manage discovery, review and data workflows. - His background includes Hatch-Waxman and pharmaceutical IP litigation, including ANDA-related disputes, joint defense coordination and review strategy. - Judd has also worked with in-house legal teams and outside counsel in banking and finance, e-commerce and other corporate environments. - His work has included internal investigations, employee departure workflows, contract and policy review, HR document updates and other data-heavy legal projects. - IntrepidX says its services cover eDiscovery, forensics, court reporting and managed document review. - The company highlighted its Relativity-related workflow tools and its XSuite applications, which are designed to reduce friction across the eDiscovery lifecycle. - XSuite includes near-instant document viewing with page-load times as fast as 4 milliseconds, integrated coding and review workflows, built-in translation, advanced text search and image highlighting. - XSuite also includes AI-powered OCR that extracts text from handwritten notes, degraded scans and complex legacy documents that traditional OCR often misses. - IntrepidX said Judd previously worked with CEO Parkash Khatri and other members of the leadership team earlier in his career. - The company said that history gives Judd a strong connection to its culture, technical approach and client-service model. - Khatri said Judd brings market knowledge, client relationships and specialized experience aligned with IntrepidX’s direction. - Judd said he was attracted to the company because the specialization is real and the team is hands-on and relationship-driven. - Judd also said the combination of expertise, discretion and technology matters in markets like pharmaceutical litigation, banking and finance and e-commerce.

Between the lines: - IntrepidX is signaling that it wants more than generic staffing for document review and discovery projects. - The company is leaning into niche legal workflows where subject-matter knowledge can matter as much as platform features. - Judd’s background suggests IntrepidX is prioritizing relationships with law firms and corporate legal departments that need specialized support, not just volume processing.

What's next: - IntrepidX will likely use Judd to deepen relationships in pharmaceutical litigation and other regulated-industry matters. - The company also appears set to keep investing in technology-enabled workflows and purpose-built applications for eDiscovery clients. - Judd said corporate legal teams often face data problems outside active litigation that still require defensible process and careful handling of sensitive information, pointing to another growth area for IntrepidX.

The bottom line: - IntrepidX is betting that specialized talent plus workflow technology will help it win more complex legal work in pharmaceuticals and other data-sensitive sectors.

More information